Curetis Prepping Second European Multiplex MDx Panel, Enrolling Trial for First US Panel | GenomeWeb

This article has been updated from a previous version to correct Curetis' planned timeline for US regulatory clearance of its platform.

Having established commercial sales of its Unyvero P50 highly multiplexed pneumonia molecular testing panel in Europe, German molecular diagnostics firm Curetis is now well underway in its efforts to enroll approximately 2,000 patients in the US for a prospective clinical trial to support a regulatory submission for a similar test to the US Food and Drug Administration.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.